Literature DB >> 16270629

VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation.

Christof Geisen1, Matthias Watzka, Katja Sittinger, Michael Steffens, Laurynas Daugela, Erhard Seifried, Clemens R Müller, Thomas F Wienker, Johannes Oldenburg.   

Abstract

In order to elucidate the role of VCORC1 sequence variants in warfarin sensitivity, we established a complete SNP map of the VKORC1 gene locus in 200 blood donors from Western Germany. Nearly all of the genetic variability of the VKORC1 gene in Europeans is reflected by three main haplotypes. Recently described polymorphisms associated with low warfarin dose requirement (dbSNP:rs9934438; dbSNP:rs17878363) were found in complete linkage disequilibrium with the VKORC1*2 haplotype. In two patient cohorts of European origin with either increased coumarin sensitivity (n= 14) or partial coumarin resistance (n=36) the VKORC1*2 frequency varied highly significant between the two groups and also when compared to 200 blood donor controls (coumarin sensitive 96%, coumarin resistant 7%, controls 42%) thus demonstrating a strong association between these two phenotypes and the VKORC1 haplotype (p = 1.6 x 10(-8) for coumarin sensitive and p = 1.9 x 10(-8) for coumarin resistant). Analysis of database derived VKORC1 genotypes of African Americans and Chinese revealed that haplotype frequencies in these populations differ significantly from the European sample (for VKORC1*2: Europeans 42%, Chinese 95%, African Americans 14%). These observations suggest VKORC1 as principal genetic modulator of the ethnic differences in warfarin response. Since hereditary pharmacodynamic (VKORC1) and pharmacokinetic (CYP2C9) factors account for up to 50% of the inter-individual variability of the warfarin response, these genetic markers may serve as clinically relevant predictors of warfarin dosing in future studies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16270629     DOI: 10.1160/TH05-04-0290

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  56 in total

1.  The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements in an adult Turkish population.

Authors:  Nihat Ozer; Nese Cam; Burak Tangurek; Songul Ozer; Huseyin Uyarel; Dilaver Oz; Mehmet Rasit Guney; Figen Ciloglu
Journal:  Heart Vessels       Date:  2010-03-26       Impact factor: 2.037

Review 2.  HapMap, pharmacogenomics, and the goal of personalized prescribing.

Authors:  Kevin M O'Shaughnessy
Journal:  Br J Clin Pharmacol       Date:  2006-06       Impact factor: 4.335

Review 3.  Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Walter Ageno; Alexander S Gallus; Ann Wittkowsky; Mark Crowther; Elaine M Hylek; Gualtiero Palareti
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 4.  The future prospects of pharmacogenetics in oral anticoagulation therapy.

Authors:  Farhad Kamali; Munir Pirmohamed
Journal:  Br J Clin Pharmacol       Date:  2006-06       Impact factor: 4.335

5.  Acenocoumarol sensitivity and pharmacokinetic characterization of CYP2C9 *5/*8,*8/*11,*9/*11 and VKORC1*2 in black African healthy Beninese subjects.

Authors:  Aurel Constant Allabi; Yves Horsmans; Jean-Claude Alvarez; André Bigot; Roger K Verbeeck; Umit Yasar; Jean-Luc Gala
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2011-08-03       Impact factor: 2.441

6.  Increased frequency of CYP2C9 variant alleles and homozygous VKORC1*2B carriers in warfarin-treated patients with excessive INR response.

Authors:  Espen Molden; Cecilie Okkenhaug; Erik Ekker Solberg
Journal:  Eur J Clin Pharmacol       Date:  2010-03-31       Impact factor: 2.953

7.  Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans.

Authors:  Nita A Limdi; Donna K Arnett; Joyce A Goldstein; T Mark Beasley; Gerald McGwin; Brian K Adler; Ronald T Acton
Journal:  Pharmacogenomics       Date:  2008-05       Impact factor: 2.533

8.  VKORC1-1639A allele influences warfarin maintenance dosage among Blacks receiving warfarin anticoagulation: a retrospective cohort study.

Authors:  Fatima Donia Mili; Tenecia Allen; Paula Weinstein Wadell; W Craig Hooper; Christine De Staercke; Christopher J Bean; Cathy Lally; Harland Austin; Nanette K Wenger
Journal:  Future Cardiol       Date:  2017-12-08

9.  Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy.

Authors:  N A Limdi; H Wiener; J A Goldstein; R T Acton; T M Beasley
Journal:  Blood Cells Mol Dis       Date:  2009-03-17       Impact factor: 3.039

10.  Higher frequency of genetic variants conferring increased risk for ADRs for commonly used drugs treating cancer, AIDS and tuberculosis in persons of African descent.

Authors:  F Aminkeng; C J D Ross; S R Rassekh; L R Brunham; J Sistonen; M-P Dube; M Ibrahim; T B Nyambo; S A Omar; A Froment; J-M Bodo; S Tishkoff; B C Carleton; M R Hayden
Journal:  Pharmacogenomics J       Date:  2013-04-16       Impact factor: 3.550

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.